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Background: Post-transplant anemia (PTA) has long been a less-recognized complication in kidney transplant recip-
ients, and its prevalence also tends to be underestimated. This study sought to evaluate the prevalence, manage-
ment, and risk factors of PTA from a group of long-term follow-up Chinese kidney transplant recipients.
Methods: One hundred and fifty-four adult kidney transplant recipients were followed up at Fuzhou General Hos-
pital, China, and retrospectively studied.
Results: PTA prevalence at transplant and at 5-yearly time points after transplantation were 45.5%, 10.7%, 9.6%,
14.8%, 13.5%, and 19.6%, respectively. Overall, 38.3% of patients had been anemic at least once during the follow-
up period, and 42% of these patients had recurrent anemia. Correlation analysis indicated that hemoglobin levels
were associated with graft function. No correlations between anemia and age, gender, immunosuppressive regi-
mens, or antihypertensive agents were observed. Binary logistic regression analysis suggested that serum creatinine
and blood urea nitrogen were associated with the diagnosis of anemia at 1 year post-transplant. At 5 years post-
transplant, only serum creatinine concentrations correlated with anemia. Although iron drugs are frequently used,
erythropoietin was rarely administered in those anemic patients suffering poor graft function that necessitated such
therapies.
Conclusions: The prevalence of PTA is noticeably high, and impaired kidney graft function seemed to be the major
risk factor for anemia. There is an urgent need to improve current PTA management and to establish modified
guidelines for this common complication in kidney transplant recipients.
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In the first few weeks, and even months, after trans-
plantation, it is relatively common for kidney transplant
recipients to suffer from post-transplant anemia (PTA)
due to blood loss from the surgical procedure and fre-
quent blood sampling for repeated tests. Other factors,
such as uremic toxins, iron deficiency, and erythropoi-
etin resistance, may also account for the high incidence
of PTA in this time period [1]. Despite the restoration of
normal hemoglobin levels achieved in most patients with
well-functioning grafts, we observed that a number of
kidney transplant recipients developed anemia. Previous* Correspondence: doctortjm@yahoo.com
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reproduction in any medium, provided the orstudies suggest that anemia can raise the risk of cardio-
vascular events in patients on hemodialysis, and cardio-
vascular diseases have been reported as the primary
cause of death in kidney transplant recipients. It is there-
fore reasonable to suggest that anemia may harm the
survival and quality of life of kidney transplant recipients
through the same mechanism that affects dialysis pa-
tients [2]. If this is correct, treating anemia may offer
improved clinical outcomes for kidney transplant recipi-
ents. However, data on the prevalence of PTA and its
current management are neither adequate nor globally
applicable, since different populations and diagnostic cri-
teria have been used.
The aim of this study was to gain insight into the
prevalence and risk factors of anemia from a group of. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ents, and to discuss the current management of this
problem.Methods
One hundred and fifty-four adult deceased-donor kidney
transplant recipients who underwent a kidney transplant
between January 2005 and May 2008 were followed up
at Fuzhou General Hospital, China, and enrolled if there
was the potential for at least 5 years’ post-transplant
follow-up. Of these patients, 14 died and 16 had graft
loss prior to their 5-year post-transplant time point, and
another six were lost to follow-up for various reasons.
Demographic and clinical data of patients at transplant
and in the subsequent 5 years during follow-up were re-
trieved (data being collected from office visit records of
each patient at the date closest to that of transplantation,
which was ± 1 month at the first and second year, and
extended to ± 3 months for later years).
Patients were diagnosed as anemic according to the
normative values established by the Chinese Society of
Hematology [3], which are 12 g/dL for males and 11 g/dL
for females. Anemic patients were further grouped as
moderate or severe if their hemoglobin levels were below
the lower limit of normal, and above 9.0 g/dL or below
9.0 g/dL, respectively. Anemia that developed 2 years or
more after its first occurrence was defined as recurrent.
Other clinical information, such as age, gender, weight,
serum creatinine (Scr) levels, blood urea nitrogen (BUN)
levels, calculated creatinine clearance (Ccr) using the
Cockcroft–Gault equation, immunosuppressive regimens,
and angiotensin-converting-enzyme inhibitors (ACEI) or
angiotensin receptor blockers (ARB), were also recorded
to assess their impact on hemoglobin levels and the diag-
nosis of PTA.Table 1 Patients’ demographic data and anemia status at tra
Year post-transplant 0 1
Total (n) 154 140
Age (years) 38.1 ± 10.3 38.8 ± 10.4 3
Gender (male/female) 109/45 98/42
Immunosuppressive
CsA + AZT + pred 30 (19.5%) 25 (17.9%) 2
CsA + MMF + pred 89 (57.8%) 81 (58.6%) 8
Tac + MMF + pred 32 (20.8%) 31 (22.1%) 3
Tac + AZT + pred 3 (1.9%) 2 (2%)




AZT, azathioprine; CsA, cyclosporin A; Hb, hemoglobin; MMF, mycophenolate mofetFor analysis of the management of PTA, data regarding
iron drugs and erythropoietin therapy were entered.
All patients gave signed informed consent. The study
was approved by the Fuzhou General Hospital Institute
Review Board (IRB00006161).
Statistical analysis
Student t-tests or Mann–Whitney U tests were used for
comparisons between two continuous variables. Chi-
square tests were used for the detection of differences
between proportions. Repeated measures ANOVA were
used to detect differences among the means of variables
of interest at each time point. Pearson’s or Spearman’s
correlation coefficients were chosen to determine whe-
ther a relationship existed between two variables. All
statistical analyses were performed using SPSS 11.0 soft-
ware (IBM, Armonk, NY, USA). A P value of <0.05 was
considered statistically significant.
Results
Patients’ demographic data and the status of anemia at
transplant and during follow-up are shown in Table 1.
The mean duration before follow-up was 4.3 ± 1.7 years.
Seventeen patients developed delayed graft function. At
transplant, most patients (57.8%) received triple ther-
apy consisting of cyclosporin A, mycophenolate mofetil
(MMF), and prednisone, and 19.5% received a combination
of cyclosporin A, azathioprine, and prednisone. Tacrolimus
was not used as often as cyclosporin A at Fuzhou General
Hospital, thus 20.8% of patients received a combination of
tacrolimus, MMF, and prednisone, and a few patients
(1.9%) received a combination of tacrolimus, azathioprine,
and prednisone.
Patients at transplant had the highest prevalence
(45.5%) of anemia for all recorded time points. In the
proceeding 5 years, 38.3% of patients had at least onensplant and at each year of follow-up
2 3 4 5
136 128 126 118
9.9 ± 10.4 40.0 ± 9.9 41.1 ± 9.9 41.9 ± 10.0
97/39 89/39 89/37 85/33
0 (14.7%) 17 (13.3%) 16 (12.7%) 14 (11.9%)
4 (61.8%) 80 (62.5%) 79 (62.7%) 73 (61.9%)
0 (22.1%) 29 (22.7%) 29 (23.0%) 29 (24.6%)
2 (1.5%) 2 (1.6%) 2 (1.6%) 2 (1.7%)
13.7 ± 1.8 13.5 ± 1.9 13.4 ± 1.9 13.0 ± 2.0
13 19 17 23
9.6% 14.8% 13.5% 19.6%
il; pred, prednisone; Tac, tacrolimus.
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rent anemia. The prevalence of PTA was low in the early
years; 10.7% and 9.6% at 1 and 2 years post-transplant,
respectively. However, PTA increased over time as reflected
by the prevalence of 19.6% at 5 years post-transplant. There
was a significant (P <0.001) decrease in mean hemoglobin
levels at 5 years post-transplant compared with those at 1,
2, 3, and 4 years; 30.4% of anemic patients at the 5-year
time point had a hemoglobin level lower than 9 g/dL, but
only 6.7% and 7.7% were observed at 1 and 2 years,
respectively.
We selected the 1- and 5-year post-transplant variables
and compared them for anemic and non-anemic patients
(Table 2). Although generally considered as an important
risk factor for poor graft function, delayed graft function
did not lead to a significant difference in Ccr and the
prevalence of anemia in this study at both time points.
At 1 year post-transplant, there was a significant differ-
ence in Ccr between anemic and non-anemic patients.
Sixty percent of anemic patients had a Ccr of less than
50 mL/min/1.73 m2; whereas only 12% of non-anemic
patients showed diminished graft function. At 5 years
post-transplant, anemic patients also suffered from impaired
graft function, demonstrating higher BUN (P = 0.001) and
Scr (P <0.001) levels, and lower Ccr (P = 0.001) than non-
anemic patients. Of the seven patients with moderate
anemia or worse, six patients (85.7%) showed a Ccr less
than 50 mL/min/1.73 m2. However, poor renal excretory
function did not have a causal relationship with anemia.
There were two and four anemic patients who had Ccr
higher than 75 mL/min/1.73 m2 at 1 and 5 years post-Table 2 Comparisons between patients with or without anem
1 year post-transplant
Anemic Non-anemic
(n = 15) (n = 125)
Age (years) 38 ± 11.8 38.9 ± 10.3
Gender (male/female) 10/5 88/37
BUN (mmol/L) 10.8 ± 6.1 6.9 ± 2.0
Creatinine (mg/dL) 1.8 ± 0.6 1.3 ± 0.3
Ccr
Mean 51.1 ± 20.8 69.1 ± 17.3
>75 mL/min/1.73 m2 2 (13.3%) 40 (32%)
50 to 75 mL/min/1.73 m2 4 (26.7%) 70 (56%)




ACEI or ARB (yes/no) 1/14 19/106
Iron medicine (yes/no) 11/4 12/113
ARB, angiotensin receptor blockers; ACEI, angiotensin-converting-enzyme inhibitors
clearance; CsA, cyclosporin A; MMF, mycophenolate mofetil; Tac, tacrolimus.transplant, respectively. Some non-anemic patients did
have suboptimal graft function.
Cyclosporin A- or tacrolimus-based immunosuppres-
sion regimens, ACEI or ARB use, gender, and age (<55
versus >55 years of age) did not affect the prevalence of
anemia at either 1 or 5 years post-transplant. Female pa-
tients seemed to have lower hemoglobin levels than males
at both time points (female: 12.9 ± 1.88 g/dL, male: 13.4 ±
1.96 g/dL 1 year post-transplant; P = 0.002). At 1 year
post-transplant, tacrolimus-based immunosuppressive
treatment (P <0.001) and age <55 years (P = 0.025) were
associated with better Ccr, while no significant correlation
between Ccr and these factors were observed at 5 years
post-transplant. There was no correlation between gender
and ARB or ACEI use and Ccr at either 1 or 5 years post-
transplant.
Patients receiving cyclosporin A, MMF, and prednis-
one, and patients receiving cyclosporin A, azathioprine,
and prednisone were selected to determine which purine
synthesis inhibitor was more likely associated with
anemia. A similar prevalence of anemia was found in the
earlier 4 years between these two groups of patients. Al-
though a greater proportion of patients on MMF had
anemia at 5 years post-transplant, the difference was in-
sufficient to achieve statistical significance (MMF: 23.8%
versus azathioprine: 7.1%; P = 0.109). Of the 12 patients
who converted from azathioprine to MMF, seven patients
(58.3%) developed anemia after conversion.
Iron therapy is frequently used at our center for the
management of anemia. Overall, 87.1% of anemic pa-
tients were treated with iron drugs at transplant, andia
5 years post-transplant
P value Anemic Non-anemic P value
(n = 23) (n = 95)
0.744 40.3 ± 9.1 42.3 ± 10.2 0.385
0.766 16/7 69/26 0.769
0.001 13.5 ± 8.1 7.1 ± 2.2 <0.001
0.001 2.0 ± 0.8 1.3 ± 0.2 <0.001
<0.001 48.1 ± 21.9 65.8 ± 13.7 <0.001
0.136 4 (17.4%) 25 (26.3%) 0.372
0.032 4 (17.4%) 61 (64.2%) <0.001
<0.001 15 (65.2%) 9 (9.5%) <0.001
0.73 3/20 28/67 0.108
0.382 21/2 81/14 0.448
0.372 5/18 16/79 0.58
<0.001 17/6 6/89 <0.001
; AZT, azathioprine; BUN, blood urea nitrogen; Ccr, calculated creatinine
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cation including iron drugs at follow-up, which were
prescribed for 73.3% and 73.9% of patients with anemia
at 1 and 5 years post-transplant, respectively. Of the
non-anemic patients, a small proportion (9.6% and 6.3%
at 1 year and 5 years, respectively) also received iron
therapy. However, erythropoietin was used much less
often in kidney transplant recipients. None of the 15 pa-
tients with anemia at 1 year post-transplant received
erythropoietin. At 5 years post-transplant, only one patient
with moderate anemia (hemoglobin: 7.2 g/dL) received
erythropoietin therapy.
Univariate correlation analyses indicated that hemoglobin
levels were associated with BUN (1 year: r = −0.280,
P = 0.001; 5 years: r = −0.210, P = 0.001) and Scr (1 year:
r = −0.152, P = 0.008; 5 years: r = −0.146, P = 0.021).
Binary logistic regression analyses were performed for
variables, including gender, original renal disease, dialysis
duration, MMF levels, azathioprine doses, BUN, and Scr.
Scr correlated with the diagnosis of anemia at both 1
and 5 years post-transplant, and BUN correlated with
anemia only at 1 year post-transplant.
Discussion
Despite its potential negative effects on kidney transplant
recipients, PTA has only received moderate to mild atten-
tion. In the current study, we observed that anemia was a
widespread problem: 38.3% of patients had at least one
episode of anemia during the follow-up period, and 19.6%
of patients were anemic at 5 years post-transplant.
Kidney graft function correlated with the development
of anemia in this study, but interestingly, anemia was
present in some patients whose kidney excretory func-
tion was good; conversely, it was absent in some cases
with poor graft function. van Dullemen et al. [4] re-
ported that erythropoietin production is lowered with
the deterioration of kidney graft excretory function, while
erythropoietin resistance becomes more apparent. This
finding facilitates the understanding that anemic patients
always have decreased Ccr and higher Scr values. How-
ever, identification of these patients suggests that other
factors, rather than the excretory branch of the kidney
graft, including inappropriate erythropoietin production
resulting from delayed graft function or perhaps calcine-
urin inhibitor nephrotoxicity, may play a role in the patho-
genesis of anemia. Since no data on serum erythropoietin
assessment or graft biopsy were available in this study,
these hypotheses remain to be determined. The effect of
some much more common complications, such as poor
nutritional status or folate/vitamin B12 deficiency, may
also influence hemoglobin levels and the onset of anemia.
Overall, 38.3% of patients in this study had at least one
episode of anemia during the follow-up period. Of these,
18 patients (42%) experienced recurrent anemia at latertime points, suggesting susceptibility caused by some
persistent clinical conditions in these patients.
The PTA prevalence observed at our center at 4 and
5 years post-transplant was lower when compared with
that of previous reports [5]. The lower normative value
used in this study is one of the possible explanations,
but the more frequent administration of iron drugs for
anemic patients is also likely to benefit the results. Effi-
cacy of these medications has been substantiated by
Kahng et al. [6]. That study reported that most patients
attained normal hemoglobin levels by 8 months post-
transplant and early iron therapy reduced the incidence
of anemia, especially in females.
The primary goal of the current study was to assess
the prevalence and management of anemia in a group of
Chinese kidney transplant recipients. Therefore, whether
the routine use of iron therapy for patients at risk of
anemia can effectively prevent its occurrence without in-
creasing other morbidities is still unclear. Further pro-
spective studies are required. According to Mrug et al.
[7], the quality of life and performance remarkably im-
proves with treatment for anemia. Erythropoietin is sel-
dom used in the management of PTA, but for patients
with poor graft function and moderate to severe anemia,
erythropoietin is most likely the only efficacious medica-
tion available.
ACEI and ARB have been successfully used to treat
post-transplant erythrocytosis. Recent evidence suggests
that the angiotensin II axis plays an important role in
erythropoiesis [8], leading to the speculation that perhaps
ACEI or ARB increases the chance of anemia in kidney
transplant recipients. Other studies have suggested that
azathioprine can cause anemia in the presence of con-
comitant ACEI use [8]. However, we observed no correl-
ation between ACEI and anemia either administered with
MMF or azathioprine in the current study. This may be
partly attributed to the small number of participants in
this study. In addition, a recent study suggests the renal
benefits of losartan in kidney transplant recipients by re-
ducing urinary excretion of proteins associated with tubu-
lar damage and graft fibrosis [9]. Taken together, the use
of ACEI or ARB in kidney transplant recipients might be
carefully balanced against the level of concern of PTA.
Retrospective studies, for their own limitations, can
hardly provide accurate insight into the relative contribu-
tion of any single or combined immunosuppressive ther-
apy in the development of anemia, and their shortcomings
become even more overt when changes in immunosup-
pressive therapy have been made.
Previous studies have suggested that both MMF and
azathioprine could lead to anemia [10]. The question
then becomes which one is more likely to do so. In the
current study, there was no significant difference in
prevalence of anemia between patients receiving MMF
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aligned with two other pivotal trials where a similar inci-
dence of anemia between patients on these drugs were
reported [11,12]. Kahng et al. [6] reported that patients
on a dual therapy of MMF and prednisone had the low-
est hemoglobin levels, and patients not being treated
with MMF generally showed higher hemoglobin levels.
However, claiming MMF is worse with regard to the oc-
currence of anemia is over-simplistic because many pa-
tients convert to MMF after a decline in kidney graft
function is discovered, which can greatly confound the
analysis. Studies assessing kidney transplant recipients
who convert to MMF from azathioprine with good graft
function may be in a better position to provide more
precise information; however, no such comparisons have
been made [13-15].
Conclusions
PTA is a common complication for long-term follow-up
kidney transplant recipients, and is often overlooked by
transplant physicians. Kidney graft function is associated
with both the diagnosis of anemia and hemoglobin levels.
Iron medications should be administered in a timely man-
ner in patients with PTA, while erythropoietin therapy
should be initiated in anemic patients whose kidney grafts
have already failed to produce sufficient erythropoietin to
maintain hemoglobin levels.
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